Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coldam (also referred to as Coldan) is a topical ophthalmic formulation developed and marketed by Sigmapharm Arzneimittel. The active ingredient is naphazoline hydrochloride, a small molecule sympathomimetic amine that acts as a potent vasoconstrictor. By stimulating alpha-adrenergic receptors in the arterioles of the conjunctiva, it induces vasoconstriction, which effectively reduces swelling, congestion, and secretions. It is indicated for the symptomatic relief of non-infectious conjunctival irritation caused by environmental factors such as smoke, dust, wind, and light. The product is available as an over-the-counter medication in Austria, typically provided in a 10 ml glass bottle with a dropping pipette.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coldam.